Kitamura N, Ohkubo H, Nakanishi S
Institute for Immunology, Kyoto University Faculty of Medicine, Japan.
J Cardiovasc Pharmacol. 1987;10 Suppl 7:S49-53. doi: 10.1097/00005344-198706107-00008.
In order to investigate the structures and expressions of the angiotensinogen and kininogen genes, we have isolated cDNA and genomic clones and characterized their structures. The following results were obtained. (a) The primary structures of rat and human angiotensinogens and bovine, human, and rat kininogens were determined, and they exhibit characteristic features. (b) Angiotensinogen and alpha 1-antitrypsin are related in not only protein structures but also gene organizations. (c) Angiotensinogen mRNA is synthesized not only in the liver but also in the brain, kidney, lung, adrenal gland, and ovary. (d) Angiotensinogen mRNA markedly increased in the liver but not in the brain after induction of acute inflammation. (e) Low molecular weight (LMW) and high molecular weight (HMW) kininogen mRNAs are generated from a single gene by alternative RNA processing events. (f) At least four types of kininogen mRNAs exist in rat liver. Two of them are LMW and HMW kininogen mRNAs, while the other two encode additional forms of kininogens (T-kininogens). (g) Two T-kininogen mRNAs but not LMW and HMW kininogen mRNAs dramatically increased after induction of acute inflammation, and T-kininogen turned out to be identical to alpha 1-major acute phase protein. (h) Kininogens have multifunctional domains; an amino-terminal domain for cystein proteinase inhibitor, a bradykinin moiety, and in the case of HMW kininogen a carboxyl-terminal domain for a cofactor of blood coagulation.
为了研究血管紧张素原和激肽原基因的结构与表达,我们分离了cDNA和基因组克隆并对其结构进行了表征。获得了以下结果。(a) 确定了大鼠和人血管紧张素原以及牛、人、大鼠激肽原的一级结构,它们呈现出特征性特点。(b) 血管紧张素原和α1 -抗胰蛋白酶不仅在蛋白质结构上相关,在基因组织方面也相关。(c) 血管紧张素原mRNA不仅在肝脏中合成,在脑、肾、肺、肾上腺和卵巢中也有合成。(d) 急性炎症诱导后,肝脏中血管紧张素原mRNA显著增加,而脑中未增加。(e) 低分子量(LMW)和高分子量(HMW)激肽原mRNA通过可变RNA加工事件由单个基因产生。(f) 大鼠肝脏中至少存在四种类型的激肽原mRNA。其中两种是LMW和HMW激肽原mRNA,另外两种编码激肽原的其他形式(T -激肽原)。(g) 急性炎症诱导后,两种T -激肽原mRNA显著增加,而LMW和HMW激肽原mRNA未增加,并且T -激肽原被证明与α1 -主要急性期蛋白相同。(h) 激肽原有多功能结构域;一个用于半胱氨酸蛋白酶抑制剂的氨基末端结构域、一个缓激肽部分,对于HMW激肽原还有一个用于凝血辅因子的羧基末端结构域。